NeoGenomics (NEO) announced that Natera (NTRA) voluntarily dismissed its appeal of the North Carolina District Court’s August 2025 ruling. The dismissal will leave in place the ruling in NeoGenomics’ favor. That ruling, issued by the District Court for the Middle District of North Carolina, granted NeoGenomics’ motion for summary judgment and held that Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Court dismissed Natera’s claims against NeoGenomics with prejudice and entered a declaratory judgment of invalidity with respect to both of Natera’s asserted patents.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target raised to $12 from $11 at Piper Sandler
- NeoGenomics to present RaDaR ST bridging study at ISLB 2025
- NeoGenomics price target raised to $11 from $6.50 at BofA
- NeoGenomics Reports Strong Revenue Growth Amid Rising Losses
- NeoGenomics Inc. Earnings Call: Clinical Growth Amid Pharma Challenges
